



EVIC Brasil

STUDY / PRODUCT REFERENCE: EBJ0004/08.1320

CONFIRMATION IN HUMAN OF THE SKIN COMPATIBILITY AND THE ABSENCE OF ALLERGENIC POTENTIAL OF A COSMETIC PRODUCT AFTER REPEATED APPLICATION UNDER PATCH

Human Repeated Insult Patch Test

HRIPT

YOGA CONFECCÕES LTDA.

TECIDO CETINETE

STUDY REPORT

São Paulo, April 8th, 2009.

10 pages in this report and 5 Appendices

IBP – Instituto de Bioengenharia da Pele Evic Brasil Ltda.

Av. Indianópolis, 1455 - Planalto Paulista - São Paulo - SP - CEP 04063-002 - Brazil

Phone.: (55 11) 2505-7000 - Fax: (55 11) 5071-6731 – Email: ibp-ericbrasil@ibp-ericbrasil.com.br

EFFICACY AND SECURITY LABORATORY

CONFIRMATION IN HUMAN OF THE SKIN COMPATIBILITY AND THE ABSENCE OF ALLERGENIC POTENTIAL OF A COSMETIC PRODUCT AFTER REPEATED APPLICATION UNDER PATCH

HUMAN REPEATED INSULT PATCH TEST

HRIPT

TABLE OF CONTENTS

	Pages
I AIM AND PRINCIPLE OF THE STUDY	1/10
II RELEVANCE OF THE STUDY	1/10
II.1 Ethics	1/10
II.2 The Ethics Committee Approval	1/10
II.3 Methodological Approach	1/10
II.4 Panel	1/10
II.5 Results	2/10
III TYPE OF THE STUDY	2/10
IV TEST PRODUCTS	2/10
IV.1 Total Number of Test Products	2/10
IV.2 Identification of the Test Product	2/10
IV.3 Information Concerning the Test Product	2/10
V SPONSOR	2/10
VI INVESTIGATOR CENTRE AND TECHNICAL STAFF	3/10
VI.1 Investigator Centre	3/10
VI.2 Technical Staff	3/10
VII DATES OF PERFORMANCE OF THE STUDY	3/10
VIII VOLUNTEERS	3/10
VIII.1 Number	3/10
VIII.2 Specific Inclusion Criteria	3/10
VIII.3 Specific Non Inclusion Criteria	4/10
VIII.4 Foreseen Risks	4/10
VIII.5 Benefits	4/10
IX METHODOLOGY	5/10
IX.1 Experimental Area	5/10
IX.2 Experimental Conditions of Application of the Test Product	5/10
IX.3 Chronology of the Study	5/10

IX.4	Constraints Required by the Study	6/10
IX.5	Control of the Observance of the Modalities of the Protocol	6/10
IX.6	Checking of the Absence of Allergenic Potential	6/10
X	RESULTS / DISCUSSION	8/10
X.1	Primary Cutaneous Compatibility	8/10
X.2	Cumulative Cutaneous Compatibility and Absence of Allergenic Potential	9/10
XI	CONCLUSION	9/10
XII	NOTES	9/10
XIII	BIBLIOGRAFIC REFERENCES	10/10
XIV	SIGNATURES AND DATES	10/10
APPENDICES		
Appendix 1	Typological Characteristics of the Volunteers	
Appendix 2	Control of Observance - Constraints	
Appendix 3	Cutaneous Examination and Questioning During the Induction Phase	
Appendix 4	Cutaneous Examination and Questioning During Challenge	
Appendix 5	Product Formula Supplied by the Sponsor	

I AIM AND PRINCIPLE OF THE STUDY

This study intended to check the skin compatibility and confirm the absence of allergenic potential of several cosmetic products including the product **TECIDO CETINETE** after repeated application to the skin under exaggerated experimental conditions.

The product was applied under patch for defined time. The applications were repeated eight times over a period of three consecutive weeks, period necessary for the possible induction of an allergy.

After a minimal two-week rest period, with no treatment, a single application of each product under patch, to the induction site and to a virgin site and for a defined time, enabled to reveal a possible induced allergy.

II RELEVANCE OF THE STUDY

II.1 Ethics

The study aiming at check the skin compatibility and confirming the absence of allergenic potential of the test product and the foreseeable risks incurred by the volunteers who took part in the study being minor, there was a suitability between the aim of the study, its possible risks and the potential troubles related to the modalities planned in the Protocol.

The applications were performed at the Institute by the Investigator, helped by Technician, under his authority.

II.2 The Ethics Committee Approval

The Research Ethical Committee analyzed the Clinical Study Protocol to evaluate the possible risks incurred by the volunteers who took part in the study.

After the analysis of these documents, the Committee emitted its approval for the application of the study, following the conditions described in this report.

II.3 Methodological Approach

The skin compatibility of the test product was checked by the Investigator who had appropriate experience or by a qualified and experienced Technician, under his authority. And the absence of the allergenic potential of the products was confirmed by the Investigator who has an appropriate experience.

The experimental conditions adopted created a certain occlusion and favoured the penetration of the ingredient through the skin. If some of them had an allergenic potential, this could be more easily proved by this kind of approach.

The methodology used was an adaptation from that described by Marzulli and Maibach⁽²⁾.

The patch material and the conditions of use of the products were adapted to the types of the test products in accordance with the corresponding procedure.

The experimental area chosen (back) enabled to test easily the products. The sites of application of the different products were chosen at random to get rid of the variability of the skin reactivity according to the site.

II.4 Panel

Referring to the experience acquired in the field of contact allergy to cosmetic products and to the accurate knowledge of the ingredients incorporated into the test products, the number of volunteers, defined in the Study Protocol, was acceptable to confirm, in first approach, the absence of allergenic potential of the test products.

II.5 **Results**

The results were mainly expressed as descriptive data and did not require a statistical treatment. If the test product had a good skin compatibility under these experimental conditions, by extrapolation it would be safe for human health when applied under normal conditions of use.

III **TYPE OF THE STUDY**

This monocentric study was performed in open.

The volunteer was used as its own control.

It was performed according to the standard procedure of EVIC Brasil, established for the performance of human test project.

IV **TEST PRODUCTS**

IV.1 **Total Number of Test Products**

The number of test products studied in the panel was **53**.

This report concerns only the product **TECIDO CETINETE**.

One control patch, corresponding to the type of patch material used for the concerned test product, containing an ad hoc quantity of distilled water, was applied at the same time, with the test products patches.

IV.2 **Identification of the Test Product**

Denomination	TECIDO CETINETE
EVIC BRASIL Reference	08.1320
Test product received in	11.03.2008
Batch number / Formula code	Not informed
Galenic form and organoleptic characteristics	Beige tissue
Number and Type of package	850 pieces
Content of each sample	150g

IV.3 **Information Concerning the Test Product**

The documents relating to the test product supplied with the samples were the qualitative and quantitative formula and the Sponsor's letter of agreement particularly concerning the conformity of the formula to the regulations in force and its safety.

V **SPONSOR**

YOGA CONFECÇÕES LTDA.

Avenida Grandes Lagos, 189 – Distrito Industrial II

15775-000 – Santa Fé do Sul - SP – Brazil

Phone: (55 17) 3641-9900

VI INVESTIGATOR CENTRE AND TECHNICAL STAFF

VI.1 Investigator Centre

EVIC Brasil
Av. Indianópolis, 1455 - Planalto Paulista
04063-002 - São Paulo - SP – Brasil
Phone: (55 11) 2505-7000

VI.2. Technical Staff

Investigator: Dr Adriana Vilarim Fernandes Epitácio – Medicine Doctor (Dermatologist)
Co-Investigator: Dr Carla Goulart Peron (Scientific Manager – Responsible Doctor)
Responsible Technician: Camila Cristina Canale

VII DATES OF PERFORMANCE OF THE STUDY

Beginning on: January 26th, 2009.

End on: March 4th, 2009.

VIII VOLUNTEERS

VIII.1 Number

The number of volunteers whose data would be exploitable at the end of the study was 50, with a lower acceptable limit of 49.

65 volunteers were included in the study, this way:

- Three volunteers (SAND O – V38, ROSE M – V45 e PATR C – V48) discontinued the study by personal reasons, not related to the test product;
- One volunteer (TANI M – V26) was excluded from the study by decision of the Investigator, by used anti-inflammatory during the study.

Thus:

The skin compatibility and confirmation of the absence of allergenic potential of the test product was assessed in 61 volunteers.

VIII.2 Specific Inclusion Criteria

The specific inclusion criteria, defined in the Protocol, were the following ones:

- age: 18-60 years old;
- sex: male and/or female;
- phototype (according to Fitzpatrick⁽⁶⁾): I a IV;
- healthy volunteer;
- healthy skin in the experimental area;
- signed the Informed Consent Form.

All the volunteers corresponded to these specific inclusion criteria. Their typological characteristics are defined in Appendix 1.

VIII.3 Specific Non Inclusion Criteria

The Specific Non Inclusion Criteria were the following ones:

- Cutaneous marks on the experimental area which could interfere with the assessment of skin reactions (pigmentation troubles, scar elements, over-developed pilosity, ephelides and naevi in too great quantity, sunburn.....),
- Eczematoid reaction still visible, scar or pigmentary sequelae of previous tests on the experimental area,
- Allergy to colophony, to nickel,
- Allergy or reactivity to the category of the test products,
- Demographic,
- Skin hyper-reactivity,
- Atopy,
- Reactivity to ethanol,
- Reactivity to adhesive plaster,
- Intensive sun exposure in the preceding months before the study,
- Foreknowledge of intensive sun or UVA exposure (UV lamps) during the test period,
- Foreknowledge of bath (bathtub, sea or swimming-pool), sauna or hammam sessions during the test period,
- Intensive or regular practice of one or several sports whose temporary interruption created difficulties,
- Treatment by Vitamin A acid or its derivatives within three months before the beginning of the study,
- Treatment by topical corticoids on the experimental area within eight days before the study,
- Treatment by UVA or UVB radiation within one month before the study,
- Foreknowledge of vaccination during the test period or last vaccination within three weeks before the study,
- Treatment with anti-inflammatory or antiallergic medicines within 15 days before the study,
- Participation in more than 5 tests under exaggerated use conditions (under patch) within 12 months before the study, including 3 hypoallergenicity tests at the most,
- Pregnant or lactating women.

VIII.4 Foreseen Risks

The foreseeable risks for this type of study were the possible allergic manifestation to a specific cosmetic product or the possible irritation appearing in the local of application, as redness or itching. If this had occurred, the application would be interrupted and any necessary assistance would be provided.

VIII.5 Benefits

The volunteer did not have any direct benefit with this study.

IX METHODOLOGY

The study was conducted in accordance to the test method **ME-001 – Tolerância Cutânea Após Única Aplicação** and **ME-002 – Verificação da Ausência do Potencial Alergênico**.

IX.1 Experimental Area

The chosen experimental area was the back.

The site of application of the product was chosen by the Investigator, Co-Investigator, Responsible Researcher or Technician, under his authority. Skin appearance was taken into account and the areas of friction with clothes were avoided.

Each product was applied by the Responsible Researcher or Technician, under the Investigator's authority, to one of the sites localized by a clockwise distribution, altering of one rank from a subject to another.

IX.2 Experimental Conditions of Application of the Test Product

The experimental conditions, defined in the protocol, were the following ones:

Patch Material	Experimental Conditions of Use	Quantity Applied
Trumed®	As it is	160µL

- Semi-occlusive patch - Trumed® : absorbent support in Webril® on which the product was put down (160 µl or approximately 160 mg), kept in position by a non woven medical adhesive (surface: 400 mm²).

The quantities of product had to be measured with a single use syringe.

All the experimental conditions of application at the Institute, defined in the Protocol, were respected.

IX.3 Chronology of the Study

The applications of the test product and the removal of the patches were performed by the Responsible Researcher or the Technician, under the Investigator's authority.

IX.3.1 induction phase: three consecutive weeks

- application of the product to a perfectly delimited site, under patch on D1, D3, D5, D8, D10, D12, D15, D17, D19.
- patch removal:
 - after forty eight hours of contact on D3, D5, D10, D12, D17, D19.
 - after seventy two hours of contact on D8, D15.
- Controls: skin examination and questioning before patching on D1 and about fifteen minutes (or more, if redness appeared after removal of the patch), after patch removal on D3, D5, D8, D10, D12, D15, D17 and D19.

IX.3.2 rest period: two consecutive weeks at least (four weeks at the most)

- no application of product.

IX.3.3 challenge: one week

- application of the product to a perfectly delimited virgin site and to the site defined for the induction phase, under patch on D36.
- patch removal after forty eight hours of contact on D38.
- Control: skin exam and questioning of volunteers before patching on D36 and about fifteen minutes (or more, if redness appeared after removal of the patch), after patch removal in D38, D39, D40 (48, 72 and 96 hours respectively, after application).

IX.4 Constraints Required by the Study

The constraints imposed on the volunteers were the following ones:

- No application of other products (than the tested one) to the experimental area;
- No wearing of too tight or restraining clothes on the experimental area, liable to produce frictions and to cause unsticking of the patch;
- No bath (bathtub or swimming-pool or sea), no hammam or sauna sessions during the study;
- If shower, protection of the experimental area or no violent projection of water and no application of soap to the experimental area to avoid patch removal or appearance of intercurrent phenomena and very gentle wiping if necessary;
- No excessive sweating and no intensive sport liable to cause unsticking of the patch;
- No intensive sun or UVA exposure (UV lamps) during the study, especially after patch removal;
- Neither anti-allergic, anti-inflammatory (systemic or topical corticotherapy...) treatment nor treatment with patent medicines containing Vitamin A acid or its derivatives during the study (if therapeutic requirement: exclusion foreseen);
- No vaccination during the study;
- No change in hygiene/care habits or substitution of the habitual hygiene/care products.

All the constraints required by the study, defined in the Protocol, were respected by the volunteers.

IX.5. Control of the Observance of the Modalities of the Protocol

The Investigator confirms the respect of the constraints.

The volunteers were questioned at the end of the study. The Investigator assessed the importance of the possible deviations in comparison with the experimental conditions required at the beginning of the study.

The synthesis of the answers obtained was enclosed in Appendix 2.

All the deviations from the protocol were analysed and the Investigator assessed their effect on the validity of the results.

All the constraints of the study, defined in the Protocol, were respected by the volunteers.

IX.6 Checking of the Absence of Allergenic Potential

IX.6.1 Frequency of the examinations

The skin examination and joint questioning had to be performed by the dermatologist helped by the co-investigator or the technician in charge of the study.

The examination had to be performed, visually under standard "daylight", according to the frequency mentioned on paragraph IX.3.

All the examinations were performed in accordance with the conditions defined in the Protocol.

IX.6.2 Expression of the results of the skin examination and questioning

The expression of the results of the skin examination and questioning was that defined for this type of study in accordance with the corresponding procedure.

In case of reactivity:

– **the main visible signs were noted, i.e. :**

Erythema, Œdema, Vesicle, Bulla, Papule, Scab, Dryness, Coloration, Soap effect.

The intensity of the **erythema and oedema** was assessed according to an ordinal scale: slight, moderate, severe.

The appearance of the **erythema** was specified: diffuse, punctuated, peripheral (around the application site).

The importance of the number of **vesicles and papules** was assessed according to an ordinal scale: 1 to 2 vesicles or papules, more than 2 vesicles or papules.

Bulla, scab, dryness, coloration and soap effect were described.

The importance of the **dryness and coloration** was assessed according to an ordinal scale: slight, moderate, severe.

– **the main sensations of discomfort were described, i.e. :**

Heating, Stinging, Pruritus (itching).

The results were expressed:

- **in percentage of reactive volunteers** : for this calculation only the visible signs of reactivity were taken into account : erythema, oedema, vesicle, bulla, papule, scab.
- **in a descriptive manner** for the other visible signs or for the sensations of discomfort : when the frequency of appearance of these signs justified it, the percentage of reactive volunteers was possibly calculated.

IX.6.3 Interpretation of the results of the skin examination and questioning

All the volunteers included in the study were taken into account to confirm the skin compatibility of the test product as long as they were submitted at least to one post application examination at the defined time or else.

All the volunteers included in the study were taken into account to confirm the absence of allergenic potential of the test product (in absence of allergic reaction during the induction phase) as long as they were submitted to the challenge.

The interpretation of the results of the skin examination and questioning was that defined for this type of study in accordance with the corresponding procedure.

The possible reactions observed during the induction phase were either **irritation reactions** or **revelation of an allergy previously contracted or revelation of an allergy precociously induced** by the test product.

The possible reactions observed during the challenge on the "virgin" site were compared to those observed on the "induction" site at the same times. They were either **irritation reactions** or **revelation of an allergy induced during the induction phase** by the test product.

The nature, intensity, time of appearance, time of disappearance, location (induction site and/or virgin site) of the skin reaction were taken into account for the interpretation of the results.

To appreciate the skin compatibility and possible irritation reactions, the interpretation of the results, performed by the dermatologist helped by the co-investigator, was absolute (referring to **the experience of the investigator centre** in this field and especially to the **data acquired** on products of same cosmetic category tested under similar conditions). Each test product could therefore have a **very good, good, moderate or bad skin compatibility**.

To appreciate the allergenic potential, the interpretation of the results was partly based on the allergenicity evaluation scale established by the **ICDRG** (International Contact Dermatitis Research Group) and took into account the visible reactions (clinical signs) and the possible reactions appeared on the control site:

NT	: non tested
?+	: doubtful reaction, only slight erythema
+	: positive reaction (with no vesicle) : erythema, infiltration, sometimes some papules
++	: strong positive reaction: presence of erythema, papules, vesicles
+++	: violent positive reaction: with presence of bullae
-	: negative reaction
IR	: irritation reaction

X RESULTS / DISCUSSION

The individual data of the skin examination and questioning of the volunteers are enclosed in **Appendices 3 and 4**.

X.1 Primary Cutaneous Compatibility

In brief:

Experimental Time	Number of Reactive volunteer	Type of reactive	Measure of the Average Daily Irritation Mdis	Percentage of reactive volunteers
D3	0	/	0	0%
Maximum measure of the Average Irritation			0	

Discussion:

During the study, 61 volunteers participated of the assessment of skin compatibility after a single application, no clinical sign was observed and no discomfort sensation was related.

X.2 Cumulative Cutaneous Compatibility and Absence of Allergenic Potential

In brief:

INDUCTION PHASE	Type of Reactivity on the Induction Site	/
	Number and Percentage of Reactive Volunteers	0/0%
CHALLENGE	Type of Reactivity on the Induction Site and Virgin Site	/
	Number and Percentage of Reactive Volunteers	0/0%

Legend: / nothing to report,

Discussion:

During the study, 61 volunteers participated of the assessment of absence of allergenic potential of the test product.

In the induction phase, no volunteer presented clinical sign or discomfort sensation in the product's application site.

In the challenge phase, no volunteer presented clinical sign or discomfort sensation in the product's application site.

XI CONCLUSION

Under the experimental conditions adopted, the repeated applications of the product **TECIDO CETINETE**, under Trumed® patch, presents:

- very good skin compatibility after a single application;
- very good skin compatibility after repeated applications;
- induced no allergic reaction.

XII NOTES

- 1 The results presented in this Study Report have private significance and were applied only for the test products supplied for this study under total Sponsor's responsibility as to the veracity of information presented for this Institute.
- 2 This Study Report does not allow the use of Evic Brasil's name or brand for any end. The infringement may submit an indemnity penalty.
- 3 The Study Report reproduction may only be performed integrally with no modification. The integral or partial reproduction requires Evic Brasil's and/or Sponsor authorization.

XIII BIBLIOGRAFIC REFERENCES

- 1** MINISTÉRIO DA SAÚDE/ CONSELHO NACIONAL DE SAÚDE, Resolução Nº 196, de 10 de Outubro de 1996 – Diretrizes e Normas Regulamentadoras de Pesquisas Envolvendo Seres Humanos.
- 2** MARZULLI F.N., Maibach H.I., Human Repeated Insult Patch Test for delayed contact hypersensitivity: HRIPT.
- 3** FITZPATRICK, T. B.; Pathak, M.; Parrish, J. A. Protection of human skin against the effects of the sunburn ultraviolet (290-320nm). In Sunlight and Man, normal and abnormal photobiological responses, by Fitzpatrick T. B. & al. (editors). University of Tokyo Press, Tokyo, 751, 1994.

XIV SIGNATURES AND DATES

Investigator:

I the understand, **Dr Adriana Vilarim Fernandes Epitácio (Medicine Doctor - Dermatologist – CRM 123577)**, declare that the overall conduct of the study was carried out under my responsibility and in accordance with the principles of Good Clinical Practices For Cosmetics (International Recommendations ICH E 6, step 4, of 1/5/1996.

Quality Assurance Personnel:

I hereby, **Almir Storck Nunes (CRF 17814)**, declare that:
- the kind of study was audited according to the requirements of the Standard NBR ISO/IEC 17025.

APPENDICES 1-5

TYPOLICAL CHARACTERISTICS OF THE VOLUNTEERS

Volunteers		Age (years)	Sex F = Female M = Male	Phototype *	Healthy volunteer	Healthy skin in the experimental area
Ref.	Name/ Surname					
1	DAMA S	51	F	IV	X	X
2	IDAL M	51	F	III	X	X
3	ADRI P	33	F	III	X	X
4	ANGE S	54	F	III	X	X
5	RAQU B	53	F	IV	X	X
6	NEUZ R	52	F	II	X	X
7	ANGE R	24	F	II	X	X
8	APAR M	38	F	III	X	X
9	MART S	31	F	IV	X	X
10	DENI D	57	F	IV	X	X
11	SALV C	48	F	III	X	X
12	LOUR M	55	M	IV	X	X
13	ELIS D	55	F	III	X	X
14	SILV S	32	F	IV	X	X
15	PERL E	34	F	IV	X	X
16	MICH P	23	F	III	X	X
17	SUEL F	49	F	II	X	X
18	ROZI S	43	F	III	X	X
19	TALI D	20	F	IV	X	X
20	EDIT S	42	F	III	X	X
21	SUEL S	42	F	III	X	X
22	LILI S	42	F	III	X	X
23	MADA G	20	F	III	X	X
24	SONI L	40	F	III	X	X

TYOLOGICAL CHARACTERISTICS OF THE VOLUNTEERS

Volunteers		Age (years)	Sex F = Female M = Male	Phototype *	Healthy volunteer	Healthy skin in the experimental area
Ref.	Name/ Surname					
25	CRIS F	45	F	III	X	X
26	TANI M	43	F	IV	X	X
27	ANAE D	34	F	III	X	X
28	ROSE B	39	F	III	X	X
29	FERN S	42	F	III	X	X
30	ROSI L	35	F	III	X	X
31	NEID S	50	F	IV	X	X
32	ROSE F	35	F	III	X	X
33	LUCI P	45	F	III	X	X
34	TELM D	39	F	III	X	X
35	MARC S	36	F	III	X	X
36	ANAM F	55	F	III	X	X
37	MARC A	24	F	III	X	X
38	SAND O	33	F	III	X	X
39	NEID P	44	F	III	X	X
40	JANA D	37	F	IV	X	X
41	GENE S	46	F	III	X	X
42	SIMO F	35	F	III	X	X
43	RAQU S	19	F	III	X	X
44	ANAM S	32	F	IV	X	X
45	ROSE Y	42	F	III	X	X
46	PRIS B	21	F	III	X	X
47	ADRI E	36	F	IV	X	X
48	PATR C	37	F	III	X	X

TYPOLICAL CHARACTERISTICS OF THE VOLUNTEERS

Volunteers		Age (years)	Sex F = Female M = Male	Phototype *	Healthy volunteer	Healthy skin in the experimental area
Ref.	Name/ Surname					
49	SIMO R	50	F	III	X	X
50	MONI L	27	F	III	X	X
51	EDGA S	43	M	III	X	X
52	JOSE R	36	M	IV	X	X
53	SIMO P	59	F	III	X	X
54	TELM R	48	F	III	X	X
55	APAR F	52	F	III	X	X
56	MART F	40	F	III	X	X
57	ROSA S	35	F	III	X	X
58	MARC S	42	F	III	X	X
59	APAR S	42	F	III	X	X
60	GRAÇ M	45	F	III	X	X
61	SONI S	50	F	III	X	X
62	APAR C	42	F	III	X	X
63	FATI C	39	F	IV	X	X
64	DAYA S	41	F	III	X	X
65	DOMI S	50	F	III	X	X

Legend:



Exclusion

***PHOTOTYPE ACCORDING TO THE FITZPATRICK'S CLASSIFICATION⁽³⁾**

Type	Hair	Skin	Freckles	Sunburns
I	red	light	+++	constant; no tan
II	fair	clear	++	frequent; slight tan
III	fair brown	clear	+	inconstant; slight to mat tan
IV	dark	mat	0	none; dark mat tan
V	black and frizzy	black	0	0

**CONTROL OF OBSERVANCE
Constraints**

Constraints (61 exploitable results)	Number of volunteers who respected the constraints	Percentage of volunteers who respected the constraints
<p>Application of other products (than the tested one) to the experimental area.</p> <p>Deviations : None</p>	61	100%
<p>Wearing of too tight or restraining clothes on the experimental area, liable to produce frictions and to cause unsticking of the patch.</p> <p>Deviations : None</p>	61	100%
<p>Bath (bathtub or swimming-pool or sea), no hammam or sauna sessions during the study.</p> <p>Deviations : None</p>	61	100%
<p>Excessive sweating and no intensive sport liable to cause unsticking of the patch</p> <p>Deviations : None</p>	61	100%
<p>If shower, protection of the experimental area or no violent projection of water and no application of soap to the experimental area to avoid patch removal or appearance of intercurrent phenomena and very gentle wiping if necessary.</p> <p>Deviations : None</p>	61	100%
<p>Intensive sun or UVA exposure (UV lamps) during the study, especially after patch removal.</p> <p>Deviations : None</p>	61	100%
<p>Neither anti-allergic, anti-inflammatory (systemic or topical corticotherapy...) treatment nor treatment with patent medicines containing Vitamin A acid or its derivatives during the study.</p> <p>Deviations : None</p>	61	100%
<p>Vaccination during the study.</p> <p>Deviations : None</p>	61	100%
<p>Change in hygiene/care habits or substitution of the habitual hygiene/care products.</p> <p>Deviations : None</p>	61	100%

CUTANEOUS EXAMINATION AND QUESTIONING DURING THE INDUCTION PHASE

Volunteers	Reactivity							
Ref.	D3	D5	D8	D10	D12	D15	D17	D19
49	/	/	/	/	/	/	/	/
50	/	/	/	/	/	/	/	/
51	/	/	/	/	/	/	/	/
52	/	/	/	/	/	/	/	/
53	/	/	/	/	/	/	/	/
54	/	/	/	/	/	/	/	/
55	/	/	/	/	/	/	/	/
56	/	/	/	/	/	/	/	/
57	/	/	/	/	/	/	/	/
58	/	/	/	/	/	/	/	/
59	/	/	/	/	/	/	/	/
60	/	/	/	/	/	/	/	/
61	/	/	/	/	/	/	/	/
62	/	/	/	/	/	/	/	/
63	/	/	/	/	/	/	/	/
64	/	/	/	/	/	/	/	/
65	/	/	/	/	/	/	/	/

Legends :

/ : nothing to report
E : Erythema
Oe : Edema
V : Vesicle
D : Dryness

Bu : Bulla
Pa : Papule
Sc : Scab
C : Coloration

S : Soap effect
Hea : Heating
St : Stinging

Pr : Pruritus
peri : peripheral
Vesicles or papules
 1 : nb = 1 or 2
 2 : nb > 2

1 : Slight intensity
 2 : Moderate intensity
 3 : Severe intensity
d : diffuse (diffusing 1 to 2 minutes around the patch)
p : punctuated



CUTANEOUS EXAMINATION AND QUESTIONING DURING CHALLENGE

Volunteers	Reactivity				Assessment according to the ICDRG criteria
	Induction site		Virgin site		
Ref.	D36	D38	D36	D38	
1	/	/	/	/	/
2	/	/	/	/	/
3	/	/	/	/	/
4	/	/	/	/	/
5	/	/	/	/	/
6	/	/	/	/	/
7	/	/	/	/	/
8	/	/	/	/	/
9	/	/	/	/	/
10	/	/	/	/	/
11	/	/	/	/	/
12	/	/	/	/	/
13	/	/	/	/	/
14	/	/	/	/	/
15	/	/	/	/	/
16	/	/	/	/	/
17	/	/	/	/	/
18	/	/	/	/	/
19	/	/	/	/	/
20	/	/	/	/	/
21	/	/	/	/	/
22	/	/	/	/	/
23	/	/	/	/	/
24	/	/	/	/	/

CUTANEOUS EXAMINATION AND QUESTIONING DURING CHALLENGE

Volunteers	Reactivity				Assessment according to the ICDRG criteria
	Induction site		Virgin site		
Ref.	D36	D38	D36	D38	
25	/	/	/	/	/
26	/	/	/	/	/
27	/	/	/	/	/
28	/	/	/	/	/
29	/	/	/	/	/
30	/	/	/	/	/
31	/	/	/	/	/
32	/	/	/	/	/
33	/	/	/	/	/
34	/	/	/	/	/
35	/	/	/	/	/
36	/	/	/	/	/
37	/	/	/	/	/
38	/	/	/	/	/
39	/	/	/	/	/
40	/	/	/	/	/
41	/	/	/	/	/
42	/	/	/	/	/
43	/	/	/	/	/
44	/	/	/	/	/
45	/	/	/	/	/
46	/	/	/	/	/
47	/	/	/	/	/
48	/	/	/	/	/

CUTANEOUS EXAMINATION AND QUESTIONING DURING CHALLENGE

Volunteers	Reactivity				Assessment according to the ICDRG criteria
	Induction site		Virgin site		
Ref.	D36	D38	D36	D38	
49	/	/	/	/	/
50	/	/	/	/	/
51	/	/	/	/	/
52	/	/	/	/	/
53	/	/	/	/	/
54	/	/	/	/	/
55	/	/	/	/	/
56	/	/	/	/	/
57	/	/	/	/	/
58	/	/	/	/	/
59	/	/	/	/	/
60	/	/	/	/	/
61	/	/	/	/	/
62	/	/	/	/	/
63	/	/	/	/	/
64	/	/	/	/	/
65	/	/	/	/	/

Legends :

/ : nothing to report
E : Erythema
Oe : Œdema
V : Vesicle
D : Dryness

Bu : Bulla
Pa : Papule
Sc : Scab
C : Coloration

1 : Slight intensity
2 : Moderate intensity
3 : Severe intensity
d : diffuse (diffusing 1 to 2 minutes around the patch)
p : punctuated



S : Soap effect
Hea : Heating
St : Stinging

Pr : Pruritus
peri : peripheral
Vesicles or papules
1 : nb = 1 or 2
2 : nb > 2

PRODUCT FORMULA SUPPLIED BY THE SPONSOR



Yoga Confeções Ltda.

Av. Grandes Lagos nº 189, Distrito Industrial II – Santa Fé do Sul/SP.

CEP. 15775-000 - Fone: (17) 3641 9900 - Fax: (17) 36419905

e-mail: www.yoga@yoga.ind.br - [http:// www.yoga.ind.br](http://www.yoga.ind.br)

Santa Fé do Sul/SP, Dia 08 de Dezembro de 2008.

Composição do tecido Cetinete:

- **90% Poliamida**
- **10% Elastano**

A large, faint watermark of the YOGA logo and a yoga silhouette is centered on the page. The word "YOGA" is written in a large, bold, sans-serif font, with a small circular logo containing the letters "YOGA" positioned above the letter "A". The silhouette of a person in a yoga pose is overlaid on the text.

Rosana Miguel Garcia

Yoga Confeções Ltda.